256 related articles for article (PubMed ID: 32476509)
21. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
Lim S; Taskinen MR; Borén J
Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
[TBL] [Abstract][Full Text] [Related]
22. Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.
Zhao F
Adv Exp Med Biol; 2018; 1061():79-93. PubMed ID: 29956208
[TBL] [Abstract][Full Text] [Related]
23. A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression.
Ramezani M; Zobeiry M; Abdolahi S; Hatami B; Zali MR; Baghaei K
Pathol Res Pract; 2023 Nov; 251():154809. PubMed ID: 37797383
[TBL] [Abstract][Full Text] [Related]
24. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
25. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Lee C; Kim J; Jung Y
Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
[TBL] [Abstract][Full Text] [Related]
26. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
[TBL] [Abstract][Full Text] [Related]
28. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Brown GT; Kleiner DE
Metabolism; 2016 Aug; 65(8):1080-6. PubMed ID: 26775559
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.
Pirola CJ; Gianotti TF; Burgueño AL; Rey-Funes M; Loidl CF; Mallardi P; Martino JS; Castaño GO; Sookoian S
Gut; 2013 Sep; 62(9):1356-63. PubMed ID: 22879518
[TBL] [Abstract][Full Text] [Related]
30. Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics.
Sookoian S; Pirola CJ
Semin Liver Dis; 2019 May; 39(2):124-140. PubMed ID: 30912099
[TBL] [Abstract][Full Text] [Related]
31. Changes in m6A in Steatotic Liver Disease.
Petri BJ; Cave MC; Klinge CM
Genes (Basel); 2023 Aug; 14(8):. PubMed ID: 37628704
[TBL] [Abstract][Full Text] [Related]
32. Epigenetics in NAFLD/NASH: Targets and therapy.
Sodum N; Kumar G; Bojja SL; Kumar N; Rao CM
Pharmacol Res; 2021 May; 167():105484. PubMed ID: 33771699
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
34. Histone Methylation Regulation as a Potential Target for Non-alcoholic Fatty Liver Disease.
Liu Y; Chen M
Curr Protein Pept Sci; 2023; 24(6):465-476. PubMed ID: 37246318
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.
Sookoian S; Rohr C; Salatino A; Dopazo H; Fernandez Gianotti T; Castaño GO; Pirola CJ
Oncotarget; 2017 Apr; 8(14):22917-22926. PubMed ID: 28206970
[TBL] [Abstract][Full Text] [Related]
36. N
Luo P; Li S; Jing W; Tu J; Long X
Trends Endocrinol Metab; 2023 Dec; 34(12):838-848. PubMed ID: 37758602
[TBL] [Abstract][Full Text] [Related]
37. Accumulation of 8-hydroxydeoxyguanosine, L-arginine and Glucose Metabolites by Liver Tumor Cells Are the Important Characteristic Features of Metabolic Syndrome and Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis.
Kakehashi A; Suzuki S; Ishii N; Okuno T; Kuwae Y; Fujioka M; Gi M; Stefanov V; Wanibuchi H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092030
[TBL] [Abstract][Full Text] [Related]
38. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
[TBL] [Abstract][Full Text] [Related]
39. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
40. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
